MAHE Manipal Team Bagged First Place at International Diabetes Summit 2023

7th International Diabetes Summit 2023 jointly organized by Chellaram Diabetes Institute Pune and International Diabetes Federation, at Pune. It was inaugurated in the presence of Swami Swaroopanandaji, Global Head – Chinmaya Mission and Dr Ashish Lele, Director CSIR-National Chemical Laboratory, Pune, along with Mr Lal Chellaram, Chairman of Chellaram Diabetes Institute, and Patron of International Diabetes Summit.

The conference was attended by more than 3000 delegates from various parts of the globe. More than 25 international speakers and nearly 100 scientific papers were presented by researchers in diabetes and its complications.
The First prize and Best Clinical Science Research Awards were bagged by the Manipal Academy of Higher Education (MAHE), Manipal team on “Novel Medical Laser Shoe Photo biomodulation on Neuropathic Pain and Plantar Pressure Profile in Type 2 Diabetes Mellitus with Peripheral Neuropathy”, a cost-effective medical device innovation solution to the diabetic peripheral neuropathic pain.
Lt. General (Dr.) M.D. Venkatesh, Vice Chancellor, MAHE said “MAHE is very happy with the prestigious Research award under the clinical science category, received by Dr G Arun Maiya during the 7th International Diabetes Summit jointly organized by Chellaram Diabetes Institute, Pune, and International Diabetes Federation, (IDF) Brussels, Belgium between 10th to 12th March 2023. Vice Chancellor, complimented and congratulated for the innovation developed for the diabetic peripheral neuropathic pain by Dr Maiya and the entire team MAHE”.

During the award ceremony Dr A G Unnikrishnan, DM – Endocrinology, Endocrinologist and CEO at Chellaram Diabetes Institute. Professor Andrew Boulton, Consultant Physician (Diabetes) and Professor of Medicine, University of Manchester, Mr Lal L. Chellaram, Chairman, The Chellaram Foundation, and other dignitaries and officials were present.

This message contains information which may be confidential and privileged. Unless you are the intended recipient (or authorized to receive this message for the intended recipient), you may not use, copy, disseminate or disclose to anyone the message or any information contained in the message. If you have received the message in error, please advise the sender by reply e-mail, and delete the message. Thank you very much.